Aims: In non-operated infective endocarditis (IE), relapse may impair the outcome of the disease. The aim of the study was to evaluate the relationship between end-of-treatment (EOT) fluorodeoxyglucose positron emission tomography/computed tomography FDG-PET/CT results and relapse in non-operated IE either on native or prosthetic valve.
Methods And Results: We included 62 patients who underwent an EOT FDG-PET/CT for non-operated IE performed between 30 and 180 days of antibiotic therapy initiation. Qualitative valve assessment categorized initial and EOT FDG-PET/CT as negative or positive. Quantitative analyses were also conducted. Clinical data from medical charts were collected, including endocarditis team decision for IE diagnosis and relapse. Forty-one (66%) patients were male with a median age of 68 years (57; 80) and 42 (68%) had prosthetic valve IE. End-of-treatment FDG-PET/CT was negative in 29 and positive in 33 patients. The proportion of positive scans decreased significantly compared with initial FDG-PET/CT (53% vs. 77%, respectively, P < 0.0001). All relapses (n = 7, 11%) occurred in patients with a positive EOT FDG-PET/CT with a median delay after EOT FDG-PET/CT of 10 days (0; 45). The relapse rate was significantly lower in negative (0/29) than in positive (7/33) EOT FDG-PET/CT (P = 0.01).
Conclusion: In this series of 62 patients with non-operated IE who underwent EOT FDG-PET/CT, those with a negative scan (almost half of the study population) did not develop IE relapse after a median follow-up of 10 months. These findings need to be confirmed by prospective and larger studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ehjci/jead138 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[F]FDG PET/CT in Advanced Mantle Cell Lymphoma.
Hematol Oncol
January 2025
Nuclear Medicine Department, ASST Spedali Civili Brescia, Brescia, Italy.
Article Synopsis
- Mantle cell lymphoma (MCL) is a severe form of non-Hodgkin lymphoma with a generally poor outcome, and the effectiveness of PET/CT scans in assessing treatment response in these patients is still uncertain.
- A study analyzed data from 120 MCL patients, focusing on various PET/CT parameters to determine their impact on progression-free survival (PFS) and overall survival (OS) following treatment.
- The findings showed that metabolic response and tumor burden parameters (like metabolic tumor volume and total lesion glycolysis) are key predictors of PFS, while features related to tumor spread are important for estimating OS.
Assessing the intracranial metabolic score as a novel prognostic tool in primary CNS lymphoma with end of induction-chemotherapy F-FDG PET/CT and PET/MR.
Cancer Imaging
November 2024
Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Article Synopsis
- This study investigates the prognostic value of a new scoring system called the intracranial metabolic score (IMS) in patients with primary central nervous system lymphoma (PCNSL) who undergo end-of-therapy imaging using F-FDG PET/CT and PET/MR.
- The IMS is based on the metabolism of normal brain structures and was shown to outperform the traditional Deauville score (DS) in predicting progression-free survival (PFS) and overall survival (OS).
- Results from the study suggest that a higher IMS score is associated with worse patient outcomes, confirming the IMS as a valuable prognostic tool for assessing PCNSL treatment effectiveness.
Prospective pilot study utilizing changes in quantitative values obtained on serial fluorine-18 fluorodeoxyglucose (F-FDG) positron emission tomography-computed tomography (PET/CT) in dogs with appendicular osteosarcoma before and after stereotactic body radiation therapy (SBRT) and carboplatin chemotherapy to assess for prediction of survival and therapeutic effectiveness.
Vet Radiol Ultrasound
July 2024
VCA Canada Central Victoria Veterinary Hospital, Victoria, British Columbia, Canada.
Serial fluorine 18 fluorodeoxyglucose (F-FDG) positron emission tomography-CT (PET/CT) is commonly used in human oncology to prognosticate and evaluate for therapeutic effectiveness. In this pilot study, dogs with naturally occurring appendicular osteosarcoma were evaluated with serial F-FDG PET/CT in an attempt to assess for response to therapy, prognostic factors, and appropriateness of imaging intervals. Fourteen dogs were enrolled in the trial.
View Article and Find Full Text PDFEvaluating Outcome Prediction via Baseline, End-of-Treatment, and Delta Radiomics on PET-CT Images of Primary Mediastinal Large B-Cell Lymphoma.
Cancers (Basel)
March 2024
Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Objectives: Accurate outcome prediction is important for making informed clinical decisions in cancer treatment. In this study, we assessed the feasibility of using changes in radiomic features over time (Delta radiomics: absolute and relative) following chemotherapy, to predict relapse/progression and time to progression (TTP) of primary mediastinal large B-cell lymphoma (PMBCL) patients.
Material And Methods: Given the lack of standard staging PET scans until 2011, only 31 out of 103 PMBCL patients in our retrospective study had both pre-treatment and end-of-treatment (EoT) scans.
Evaluation of therapeutic effect and prognostic value of F-FDG PET/CT in different treatment nodes of DLBCL patients.
EJNMMI Res
February 2024
Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Background: In the present study, we aimed to investigate the role of baseline (B), interim (I) and end-of-treatment (Eot) F-FDG PET/CT in assessing the prognosis of diffuse large B cell lymphoma (DLBCL), so as to identify patients who need intensive treatment at an early stage.
Methods: A total of 127 DLBCL patients (62 men; 65 women; median age 62 years) were retrospectively analyzed in this study. Baseline (n = 127), interim (n = 127, after 3-4 cycles) and end-of-treatment (n = 53, after 6-8 cycles) PET/CT images were re-evaluated; semi-quantitative parameters such as maximum standardized uptake value of lesion-to-liver ratio (SUVmax) and lesion-to-mediastinum ratio (SUVmax), total metabolic tumor volume (TMTV) and total metabolic tumor volume (TLG) were recorded.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!